Life science companies have to future-proof their value chain by placing functions, assets and risks in locations where they are planning to have their profits taxed. Structures where profit allocations are made in tax-beneficent locations with little or no substance are no longer viable.
KPMG’s newest report on leading Life Sciences Clusters in Europe, released on 3 November 2015 at the Bio Europe Congress, reveals important differences between different countries in Europe and their attractiveness for Foreign Direct Investments for the Life Sciences Industry.
What makes a European Life Science site attractive to foreign investors? KPMG Switzerland’s Global Location Evaluation Services collaborated with Venture Valuation, a business intelligence boutique specializing in Life Sciences (LS), to analyze previously unpublished data comparing leading European LS clusters.